33797-34-1

Usage

Uses

Used in Fragrance Industry:
(3-Methoxy-2-methylphenyl)methanol is used as a fragrance ingredient for its sweet, floral scent, adding pleasant aromas to cosmetics, perfumes, and other personal care products.
Used in Solvent Applications:
(3-Methoxy-2-methylphenyl)methanol serves as a solvent in various chemical processes, leveraging its ability to dissolve other substances effectively.
Used in Chemical Synthesis:
(3-Methoxy-2-methylphenyl)methanol is utilized as an intermediate in the synthesis of other organic compounds, contributing to the creation of a wide range of chemical products.
Safety Considerations:
Given its low to moderate acute toxicity and potential irritant effects on the skin and eyes, (3-Methoxy-2-methylphenyl)methanol requires careful handling and use with appropriate safety precautions to ensure the well-being of individuals and the environment.

Upstream product

• 56724-03-9 3-methoxy-2-methyl-benzaldehyde 
• 555-31-7 aluminum isopropoxide 
• 55289-06-0 3-methoxy-2-methylbenzoic acid 
• 42981-93-1 3-methoxy-2-methylbenzoic acid methyl ester 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 55289-05-9 methyl 3-hydroxy-2-methylbenzoate 
• 603-80-5 3-hydroxy 2-methylbenzoic acid 
• 52130-17-3 3-amino-2-methylbenzoic acid 

Downstream Products

• 42981-94-2 1-(chloromethyl)-3-methoxy-2-methylbenzene 
• 56724-03-9 3-methoxy-2-methyl-benzaldehyde 
• 15159-14-5 6-methoxy-5-methyl-α-tetralone 
• 211503-45-6 4-(3-methoxy-2-methylphenyl)butanoic acid 
• 1258853-82-5 (S)-5-(3-(3-(2,3-dihydroxypropyl)-6-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride 
• 871501-24-5 N-(2,2-dimethoxyethyl)-2-(3-methoxy-2-methylphenyl)acetamide 
• 1258853-83-6 (R)-5-(3-(3-(2,3-dihydroxypropyl)-6-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride 

Relevant academic research and scientific papers

Vanadium-Catalyzed Oxidative Intramolecular Coupling of Tethered Phenols: Formation of Phenol-Dienone Products

A mild and efficient method for the vanadium-catalyzed intramolecular coupling of tethered free phenols is described. The corresponding phenol-dienone products are prepared directly in good yields with low catalyst loadings. Electronically diverse tethered phenol precursors are well tolerated, and the catalytic method was effectively applied as the key step in syntheses of three natural products and a synthetically useful morphinan alkaloid precursor.

4-benzylaminobenzenesulfonamide derivative and preparation and application thereof

The invention provides a 4-benzylaminobenzenesulfonamide derivative represented by a formula (I) or a pharmaceutically acceptable salt, a solvate or a metabolite thereof. In the formula (I), R1, R2, R3, R4, R5 and R6 are defined in the specification. The

α-Ketocarbenium Ions Derived from Orthoquinone-Containing Polycyclic Aromatic Compounds

α-Ketocarbenium ions derived from synthesized orthoquinone-containing polycyclic aromatic compounds were generated in the presence of Br?nsted acids such as sulfuric acid, trifluoromethanesulfonic acid, and fluorosulfonic acid. The prepared α-ketocarbeniu

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases

The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Following identification of a lead compound with a dihydronaphthalene central core by inducing conformational constraint, optimization of the lipophilic tail region led to the discovery of 13n as a clinical candidate that exhibited >30 000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing).

HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists

This article describes the finding of substantial upregulation of mRNA and enzymes of the cytochrome P450 1A family during a lead optimization campaign for small molecule S1P1 agonists. Fold changes in mRNA up to 10 000-fold for CYP1A1 in vivo

Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization

The discovery of 3-methoxy-9-(3′,4′,5′-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol (a benzosuberene-based analogue referred to as KGP18) was originally inspired by the natural products colchicine and combretastatin A-4 (CA4). The relative struct

ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The inventi

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, A and B are as defined herein. The invention also r

Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase

The present invention provides a 10,11-dihydrospiro[dibenzo[a,d][7]annulene-5,4′-imidazol]-5′(1′H)-one compound of formula I Also provided are methods and compositions for the inhibition of β-secretase (BACE) and the treatment of β-amyloid deposits and neurofibrillary tangles.